S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
What Is WallStreetBets and What Stocks Are They Targeting?
Trading Millionaire Reveals, “2008 Was My Most Profitable Year” (Ad)
Can You Guess Which EV Stock Is Beating Tesla ?
Closing prices for crude oil, gold and other commodities
Three Chinese corporate giants leaving NY stock exchange
27 U.S. Cities Where Stocks Yield 26% a Year (Ad)pixel
Wall Street builds on gains, heads for 4-week winning streak
Pipeline break spills 45,000 gallons of diesel in Wyoming
Judge revives Obama-era ban on coal sales from federal lands
Stop Day Trading - More Here (Ad)pixel
NASDAQ:LIFE

aTyr Pharma - LIFE Stock Forecast, Price & News

$3.54
-0.11 (-3.01%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$3.50
$3.73
50-Day Range
$2.63
$3.73
52-Week Range
$2.60
$13.10
Volume
151,734 shs
Average Volume
128,176 shs
Market Capitalization
$99.32 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$17.00

aTyr Pharma MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
515.8% Upside
$21.80 Price Target
Short Interest
Healthy
1.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.14mentions of aTyr Pharma in the last 14 days
Based on 7 Articles This Week
Insider Trading
Acquiring Shares
$43,200 Bought Last Quarter
Proj. Earnings Growth
Growing
From ($1.75) to ($1.71) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.75 out of 5 stars

Medical Sector

78th out of 1,117 stocks

Biological Products, Except Diagnostic Industry

11th out of 175 stocks

LIFE stock logo

About aTyr Pharma (NASDAQ:LIFE) Stock

aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD. It is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of solid tumors. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of efzofitimod for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.

Wall Street Analyst Weigh In

A number of brokerages have commented on LIFE. StockNews.com upgraded aTyr Pharma from a "sell" rating to a "hold" rating in a research report on Thursday, June 9th. HC Wainwright lifted their target price on aTyr Pharma from $11.00 to $35.00 and gave the company a "buy" rating in a research note on Thursday, July 21st. Finally, Piper Sandler decreased their price objective on aTyr Pharma from $19.00 to $11.00 and set an "overweight" rating for the company in a research note on Wednesday, May 18th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $21.80.

aTyr Pharma Trading Down 3.0 %

NASDAQ:LIFE traded down $0.11 on Friday, hitting $3.54. 151,734 shares of the company's stock were exchanged, compared to its average volume of 128,176. aTyr Pharma has a 52 week low of $2.60 and a 52 week high of $13.10. The stock has a market cap of $99.32 million, a price-to-earnings ratio of -1.96 and a beta of 1.52. The stock has a 50-day moving average of $3.11 and a 200-day moving average of $4.10.

aTyr Pharma (NASDAQ:LIFE - Get Rating) last posted its quarterly earnings data on Monday, May 9th. The biotechnology company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.34) by ($0.10). During the same quarter last year, the business posted ($0.51) earnings per share. As a group, analysts predict that aTyr Pharma will post -1.75 earnings per share for the current year.

Insider Activity at aTyr Pharma

In related news, CEO Sanjay Shukla acquired 15,000 shares of the firm's stock in a transaction that occurred on Friday, July 1st. The stock was acquired at an average cost of $2.88 per share, for a total transaction of $43,200.00. Following the completion of the acquisition, the chief executive officer now directly owns 40,798 shares of the company's stock, valued at approximately $117,498.24. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 4.36% of the stock is currently owned by company insiders.

Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Stock News Headlines

Is Apple Pointing to a Massive Recession in the U.S.?
Apple (AAPL) is making moves behind the scenes to prepare for a downturn…Bloomberg recently reported that the tech giant plans to freeze hiring in some divisions- while remaining cautious on spending through next year. And the thing is, Apple isn’t alone…Bottom-line: Apple might be pointing to a massive recession in the U.S. If you have any serious assets in the market, there is one critical step you must take now.
27 U.S. Cities Where Stocks Yield 26% a Year
What’s the highest-yielding stock you’ve ever owned? The dividends for these stocks have risen so fast over the years that they’re now yielding us an average of 26%! When you start getting paid 26% on your money, your financial problems tend to pretty much evaporate. pixel
aTyr Pharma Misses Q1 EPS by 11c
aTyr Pharma Q1 2022 Earnings Preview
Earnings Outlook For aTyr Pharma
See More Headlines
Receive LIFE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for aTyr Pharma and its competitors with MarketBeat's FREE daily newsletter.

LIFE Company Calendar

Last Earnings
8/09/2021
Today
8/12/2022
Next Earnings (Confirmed)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Life Sciences Tools & Services
Sector
Medical
Current Symbol
NASDAQ:LIFE
CUSIP
53217V10
Employees
49
Year Founded
2005

Price Target and Rating

Average Stock Price Forecast
$21.80
High Stock Price Forecast
$35.00
Low Stock Price Forecast
$11.00
Forecasted Upside/Downside
+380.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
5 Analysts

Profitability

Net Income
$-33,770,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$10.45 million
Book Value
$3.93 per share

Miscellaneous

Free Float
26,833,000
Market Cap
$99.32 million
Optionable
Optionable
Beta
1.52

Social Links


Key Executives

  • Dr. Sanjay S. Shukla M.D. (Age 50)
    M.S., Pres, CEO & Director
    Comp: $816.41k
  • Ms. Jill M. Broadfoot (Age 60)
    Chief Financial Officer
    Comp: $561.76k
  • Ms. Nancy E. Denyes Krueger (Age 54)
    Gen. Counsel & Corp. Sec.
    Comp: $537.59k
  • Xiang-Lei Yang Ph.D.
    Founder
  • Ms. Ashlee Dunston
    Director of Investor Relations & Corp. Communications
  • Mr. Peter Villiger
    VP of Corp. Devel.
  • Ms. Danielle Campbell
    VP of Human Resource
  • Dr. Ying J. Buechler Ph.D.
    Exec. Director of Biologics Devel. & Manufacturing
  • Dr. Melissa A. Ashlock (Age 64)
    Sr. Advisor
  • Dr. David J. King (Age 63)
    Scientific Consultant













LIFE Stock - Frequently Asked Questions

Should I buy or sell aTyr Pharma stock right now?

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for aTyr Pharma in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" LIFE shares.
View LIFE analyst ratings
or view top-rated stocks.

What is aTyr Pharma's stock price forecast for 2022?

5 Wall Street analysts have issued twelve-month price targets for aTyr Pharma's stock. Their LIFE share price forecasts range from $11.00 to $35.00. On average, they predict the company's share price to reach $21.80 in the next twelve months. This suggests a possible upside of 515.8% from the stock's current price.
View analysts price targets for LIFE
or view top-rated stocks among Wall Street analysts.

How have LIFE shares performed in 2022?

aTyr Pharma's stock was trading at $7.47 at the beginning of 2022. Since then, LIFE stock has decreased by 52.6% and is now trading at $3.54.
View the best growth stocks for 2022 here
.

When is aTyr Pharma's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our LIFE earnings forecast
.

How can I listen to aTyr Pharma's earnings call?

aTyr Pharma will be holding an earnings conference call on Monday, August 15th at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were aTyr Pharma's earnings last quarter?

aTyr Pharma, Inc. (NASDAQ:LIFE) posted its quarterly earnings results on Monday, August, 9th. The biotechnology company reported ($0.64) earnings per share for the quarter, missing analysts' consensus estimates of ($0.51) by $0.13.

When did aTyr Pharma's stock split?

aTyr Pharma shares reverse split on Monday, July 1st 2019. The 1-14 reverse split was announced on Friday, June 28th 2019. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 28th 2019. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

What is Sanjay Shukla, M.D, M.S's approval rating as aTyr Pharma's CEO?

3 employees have rated aTyr Pharma Chief Executive Officer Sanjay Shukla, M.D, M.S on Glassdoor.com. Sanjay Shukla, M.D, M.S has an approval rating of 100% among the company's employees. This puts Sanjay Shukla, M.D, M.S in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of aTyr Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other aTyr Pharma investors own include Wynn Resorts (WYNN), Biocept (BIOC), SCYNEXIS (SCYX), Idera Pharmaceuticals (IDRA), OPKO Health (OPK), Precigen (PGEN), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Aldeyra Therapeutics (ALDX).

When did aTyr Pharma IPO?

(LIFE) raised $76 million in an initial public offering on Thursday, May 7th 2015. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan and Citigroup served as the underwriters for the IPO and BMO Capital Markets and William Blair were co-managers.

What is aTyr Pharma's stock symbol?

aTyr Pharma trades on the NASDAQ under the ticker symbol "LIFE."

Who are aTyr Pharma's major shareholders?

aTyr Pharma's stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (15.00%), Group One Trading L.P. (0.00%) and D.A. Davidson & CO. (0.04%). Insiders that own company stock include Jill Marie Broadfoot, John K Clarke, Paul Schimmel and Sanjay Shukla.
View institutional ownership trends
.

How do I buy shares of aTyr Pharma?

Shares of LIFE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is aTyr Pharma's stock price today?

One share of LIFE stock can currently be purchased for approximately $3.54.

How much money does aTyr Pharma make?

aTyr Pharma (NASDAQ:LIFE) has a market capitalization of $99.32 million and generates $10.45 million in revenue each year. The biotechnology company earns $-33,770,000.00 in net income (profit) each year or ($1.81) on an earnings per share basis.

When was aTyr Pharma founded?

aTyr Pharma was founded in 2005.

How can I contact aTyr Pharma?

aTyr Pharma's mailing address is 3545 JOHN HOPKINS COURT SUITE 250, SAN DIEGO CA, 92121. The official website for the company is www.atyrpharma.com. The biotechnology company can be reached via phone at (858) 731-8389, via email at investorrelations@atyrpharma.com, or via fax at 858-731-8394.

This page (NASDAQ:LIFE) was last updated on 8/13/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.